Improvement of motor function in early Parkinson disease by safinamide

被引：83

作者：

Stocchi, F

Arnold, G

Onofrj, M

Kwiecinski, H

Szczudlik, A

Thomas, A

Bonuccelli, U

Van Dijk, A

Cattaneo, C

Sala, P

Fariello, RG

机构：

[1] Newron Pharmaceut, I-20091 Milan, Italy

[2] Univ G DAnnunzio, Dept Neurosci, Pescara, Italy

[3] Univ G DAnnunzio, IRCCS Neuromed Pozzilli IS, Pescara, Italy

[4] Univ G DAnnunzio, Movement Disorders Ctr, Dept Neurosci, Pescara, Italy

[5] Univ Pisa, Dept Neurosci, Inst Neurol, I-56100 Pisa, Italy

[6] Kendle Int Res Org, Osp Versilia, UOC Neurol, Saronna, VA, Italy

[7] Humboldt Univ, Fac Med Charite, Dept Neurol, D-10098 Berlin, Germany

[8] Univ Warsaw, Dept Neurol, PL-00325 Krakow, Poland

[9] Jagiellonian Univ, Dept Neurol, Coll Med, Krakow, Poland

来源：

NEUROLOGY | 2004年 / 63卷 / 04期

关键词：

D O I：

10.1212/01.WNL.0000134672.44217.F7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A median safinamide (SAF) dose of 70 mg/day (range 40 to 90 mg/day) increased the percentage of parkinsonian patients improving their motor scores by greater than or equal to30% from baseline (responders) after 3 months from 21.4% (placebo) to 37.5% (p<0.05, calculated by logistic regression analysis). In a subgroup of 101 patients under stable treatment with a single dopamine agonist, addition of SAF magnified the response (47.1% responders, mean 4.7-point motor score decrease; p >= 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses.

引用

页码：746 / 748

页数：3

共 10 条

[1] Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition [J].